Frontlight ResearchEarly access
Taking peoplePhase 1
PET tracer study in leg artery disease and healthy volunteers
Tests a PET tracer in leg artery disease and healthy people.
Key facts
- Who runs it
- Aplagon Oy
- Where
- Netherlands1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Safety, tolerability, and biodistribution of [89Zr]Zr-DFO-APAC (Phase 0) in subjects with peripheral arterial occlusive disease / critical limb ischemia (PAOD/CLI) and healthy volunteers – an open label PET study (CHASE-study)
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 10 people, planned
- Started
- 1 Feb 2024
- Planned end
- 31 Aug 2024
- Type of study
- Interventional
- Record updated
- 27 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with peripheral arterial occlusive disease or critical limb ischemia, and also healthy volunteers. It tests the safety and spread in the body of a PET scan tracer called [89Zr]Zr-DFO-APAC.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Peripheral arterial occlusive disease (blocked leg arteries) or critical limb ischemia (severe lack of blood flow to a limb). Healthy volunteers can also join.
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- PET tracer study in leg artery disease and healthy volunteersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 27 February 2026